June 17, 2022
According to the research report titled ‘U.S. Non-Invasive Prenatal Testing Market Research and Outlook, 2021 - Trends, Growth Opportunities, Competitive Analysis and Forecasts to 2028’, available with MarketStudyReport, the U.S. non-invasive prenatal testing market is estimated to generate returns worth USD 2.5 billion by 2028.
The rising per capita income, improved cognizance about prenatal tests, the rise in prevalence of chromosomal aneuploidies among fetuses, and advancements in the field are the factors contributing to the of the U.S. non-invasive prenatal testing industry.
Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3950419/
Furthermore, increased focus on enhancing the reimbursement scenario for NIPT, growing preference for non-invasive methodologies, and ACOG standards that advocates non-invasive prenatal testing (NIPT) for all pregnancies irrespective of any
susceptibility are all leading to market growth.
Apart from the comprehensive analysis of the key growth drivers, the report also entails the constraints and challenges prevailing in the industry, along with all the potential solutions to assist investors in generating the revenue inflow.
The report examines the entire industry in detail. It features information regarding the current trends as well as forecasts for the following years. Based on the historical statistics from 2015 to 2020, the report forecasts the developmental pattern from 2021-to 2028, addressing the significant aspects such as the volume and value of the U.S. non-invasive prenatal testing market.
The publication also contains a thorough analysis of the overall percentage of NIPT tests conducted in the United States. Additionally, a piece of extensive information on the region's average and high-risk NIPT tests is provided.
The report also gives a clear picture of the industry's regulatory framework. In addition, it delivers detailed synopses of the different reimbursement approaches prevailing in the industry.
This business intelligence document also acknowledges all the developments in the industry, including mergers & acquisitions, partnership deals, exclusive agreements, collaboration deals, distribution channels, and licensing agreements.
It evaluates the revenues accumulated by the leading players, their present product portfolios, business profiles, and the latest developments to comprehend the competitive panorama. Multiple companies are advancing their NIPT devices to generate high revenue and remain afloat in the U.S. non-invasive prenatal testing market.
The well-known organizations profiled in the report are Integrated Genetics (LabCorp), Agilent Technologies, Inc., Yourgene Health, Progenity, Inc., Centogene US LLC, Quest Diagnostics, Illumina, Inc., Ariosa Diagnostics, Inc., Invitae Corp., PerkinElmer, Inc., GenPath Diagnostics, Myriad Genetics, and Natera, Inc.